Administration of a 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor Improves Outcome in a Rat Model of Pediatric Traumatic Brain Injury

Shiyu Shu, Zhi Zhang, Dawn Spicer, Ewa Kulikowicz, Ke Hu, Savalan Babapoor-Farrokhran, Sujatha Kannan, Raymond C Koehler, Courtney Robertson

Research output: Contribution to journalArticle

Abstract

The arachidonic acid pathway metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to ischemia/reperfusion brain injury. Inhibition of 20-HETE formation can protect the developing brain from global ischemia. Here, we examined whether treatment with the 20-HETE synthesis inhibitor N-hydroxy-N-4-butyl-2-methylphenylformamidine (HET0016) can protect the immature brain from traumatic brain injury (TBI). Male rats at postnatal day 9-10 underwent controlled cortical impact followed by intraperitoneal injection with vehicle or HET0016 (1 mg/kg, 5 min and 3 h post-injury). HET0016 decreased the lesion volume by over 50% at 3 days of recovery, and this effect persisted at 30 days as the brain matured. HET0016 decreased peri-lesion gene expression of proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β]) at 1 day and increased reparative cytokine (IL-4, IL-10) expression at 3 days. It also partially preserved microglial ramified processes, consistent with less activation. HET0016 decreased contralateral hindlimb foot faults and improved outcome on the novel object recognition memory task 30 days after TBI. In cultured BV2 microglia, HET0016 attenuated the lipopolysaccharide-evoked increase in release of TNF-α. Our data show that HET0016 improves acute and long-term histologic and functional outcomes, in association with an attenuated neuroinflammatory response after contusion of an immature rat brain.

Original languageEnglish (US)
JournalDevelopmental Neuroscience
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pediatrics
Brain
Tumor Necrosis Factor-alpha
Cytokines
Contusions
Microglia
Hindlimb
Intraperitoneal Injections
Reperfusion Injury
Brain Ischemia
Interleukin-1
Arachidonic Acid
Interleukin-4
Interleukin-10
Brain Injuries
Lipopolysaccharides
Foot
Gene Expression
Wounds and Injuries
Traumatic Brain Injury

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Administration of a 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor Improves Outcome in a Rat Model of Pediatric Traumatic Brain Injury. / Shu, Shiyu; Zhang, Zhi; Spicer, Dawn; Kulikowicz, Ewa; Hu, Ke; Babapoor-Farrokhran, Savalan; Kannan, Sujatha; Koehler, Raymond C; Robertson, Courtney.

In: Developmental Neuroscience, 01.01.2019.

Research output: Contribution to journalArticle

@article{e6bd2db084a8457aa6f1a49bddd435d5,
title = "Administration of a 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor Improves Outcome in a Rat Model of Pediatric Traumatic Brain Injury",
abstract = "The arachidonic acid pathway metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to ischemia/reperfusion brain injury. Inhibition of 20-HETE formation can protect the developing brain from global ischemia. Here, we examined whether treatment with the 20-HETE synthesis inhibitor N-hydroxy-N-4-butyl-2-methylphenylformamidine (HET0016) can protect the immature brain from traumatic brain injury (TBI). Male rats at postnatal day 9-10 underwent controlled cortical impact followed by intraperitoneal injection with vehicle or HET0016 (1 mg/kg, 5 min and 3 h post-injury). HET0016 decreased the lesion volume by over 50{\%} at 3 days of recovery, and this effect persisted at 30 days as the brain matured. HET0016 decreased peri-lesion gene expression of proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β]) at 1 day and increased reparative cytokine (IL-4, IL-10) expression at 3 days. It also partially preserved microglial ramified processes, consistent with less activation. HET0016 decreased contralateral hindlimb foot faults and improved outcome on the novel object recognition memory task 30 days after TBI. In cultured BV2 microglia, HET0016 attenuated the lipopolysaccharide-evoked increase in release of TNF-α. Our data show that HET0016 improves acute and long-term histologic and functional outcomes, in association with an attenuated neuroinflammatory response after contusion of an immature rat brain.",
author = "Shiyu Shu and Zhi Zhang and Dawn Spicer and Ewa Kulikowicz and Ke Hu and Savalan Babapoor-Farrokhran and Sujatha Kannan and Koehler, {Raymond C} and Courtney Robertson",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000500895",
language = "English (US)",
journal = "Developmental Neuroscience",
issn = "0378-5866",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Administration of a 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor Improves Outcome in a Rat Model of Pediatric Traumatic Brain Injury

AU - Shu, Shiyu

AU - Zhang, Zhi

AU - Spicer, Dawn

AU - Kulikowicz, Ewa

AU - Hu, Ke

AU - Babapoor-Farrokhran, Savalan

AU - Kannan, Sujatha

AU - Koehler, Raymond C

AU - Robertson, Courtney

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The arachidonic acid pathway metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to ischemia/reperfusion brain injury. Inhibition of 20-HETE formation can protect the developing brain from global ischemia. Here, we examined whether treatment with the 20-HETE synthesis inhibitor N-hydroxy-N-4-butyl-2-methylphenylformamidine (HET0016) can protect the immature brain from traumatic brain injury (TBI). Male rats at postnatal day 9-10 underwent controlled cortical impact followed by intraperitoneal injection with vehicle or HET0016 (1 mg/kg, 5 min and 3 h post-injury). HET0016 decreased the lesion volume by over 50% at 3 days of recovery, and this effect persisted at 30 days as the brain matured. HET0016 decreased peri-lesion gene expression of proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β]) at 1 day and increased reparative cytokine (IL-4, IL-10) expression at 3 days. It also partially preserved microglial ramified processes, consistent with less activation. HET0016 decreased contralateral hindlimb foot faults and improved outcome on the novel object recognition memory task 30 days after TBI. In cultured BV2 microglia, HET0016 attenuated the lipopolysaccharide-evoked increase in release of TNF-α. Our data show that HET0016 improves acute and long-term histologic and functional outcomes, in association with an attenuated neuroinflammatory response after contusion of an immature rat brain.

AB - The arachidonic acid pathway metabolite 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to ischemia/reperfusion brain injury. Inhibition of 20-HETE formation can protect the developing brain from global ischemia. Here, we examined whether treatment with the 20-HETE synthesis inhibitor N-hydroxy-N-4-butyl-2-methylphenylformamidine (HET0016) can protect the immature brain from traumatic brain injury (TBI). Male rats at postnatal day 9-10 underwent controlled cortical impact followed by intraperitoneal injection with vehicle or HET0016 (1 mg/kg, 5 min and 3 h post-injury). HET0016 decreased the lesion volume by over 50% at 3 days of recovery, and this effect persisted at 30 days as the brain matured. HET0016 decreased peri-lesion gene expression of proinflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin-1β [IL-1β]) at 1 day and increased reparative cytokine (IL-4, IL-10) expression at 3 days. It also partially preserved microglial ramified processes, consistent with less activation. HET0016 decreased contralateral hindlimb foot faults and improved outcome on the novel object recognition memory task 30 days after TBI. In cultured BV2 microglia, HET0016 attenuated the lipopolysaccharide-evoked increase in release of TNF-α. Our data show that HET0016 improves acute and long-term histologic and functional outcomes, in association with an attenuated neuroinflammatory response after contusion of an immature rat brain.

UR - http://www.scopus.com/inward/record.url?scp=85072776118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072776118&partnerID=8YFLogxK

U2 - 10.1159/000500895

DO - 10.1159/000500895

M3 - Article

C2 - 31553983

AN - SCOPUS:85072776118

JO - Developmental Neuroscience

JF - Developmental Neuroscience

SN - 0378-5866

ER -